Ephrins and pain

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 8, 2013, Pages 879-887

  Vasileiou, Ioanna ^a   Adamakis, Ioannis ^a   Patsouris, Efstratios ^a   Theocharis, Stamatios ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Allodynia; Cancer pain; Ephrins; Hyperlagesia; Pain

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DIZOCILPINE; EPHRIN; EPHRIN B1; EPHRIN B2; EPHRIN RECEPTOR; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SMALL INTERFERING RNA; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; Z 360;

ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; CYTOKINE RELEASE; DRUG ABUSE; DRUG MISUSE; DRUG TARGETING; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; KIDNEY DISEASE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; OPIATE ADDICTION; PAIN; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN;

ANIMALS; EPHRINS; HUMANS; PAIN;

EID: 84880362479     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.801456     Document Type: Review

References (60)

1. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413(6852):203-10 (Pubitemid 32867885)
2. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science (New York, NY) 2000;288(5472):1765-9
3. Mogil JS, Yu L, Basbaum AI. Pain genes?: natural variation and transgenic mutants. Annu Rev Neurosci 2000;23:777-811 (Pubitemid 30350060)
4. Koltzenburg M, Scadding J. Neuropathic pain. Curr Opin Neurol 2001;14(5):641-7 (Pubitemid 32964585)
5. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001;95(1):241-9 (Pubitemid 32623017)
6. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140(6):441-51 (Pubitemid 38327332)
7. Zeilhofer HU. Loss of glycinergic and GABAergic inhibition in chronic pain-contributions of inflammation and microglia. Int Immunopharmacol 2008;8(2):182-7
8. Song GH, Venkatraman V, Ho KY, et al. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain 2006;126(1-3):79-90 (Pubitemid 44751957)
9. Merskey H, Watson GD. The lateralisation of pain. Pain 1979;7(3):271-80 (Pubitemid 10126484)
10. Jensen KB, Kosek E, Petzke F, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009;144(1-2):95-100
11. Wilson JA, Garry EM, Anderson HA, et al. NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists. Pain 2005;117(3):421-32 (Pubitemid 41383537)
12. Abe T, Matsumura S, Katano T, et al. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Eur J Neurosci 2005;22(6):1445-54 (Pubitemid 41442416)
13. Guo W, Zou S, Guan Y, et al. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci 2002;22(14):6208-17 (Pubitemid 35387661)
14. Chou R, Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147(7):492-504 (Pubitemid 351664520)
15. Gatchel RJ, Peng YB, Peters ML, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007;133(4):581-624
16. Molton IR, Graham C, Stoelb BL, Jensen MP. Current psychological approaches to the management of chronic pain. Curr Opin Anaesthesiol 2007;20(5):485-9 (Pubitemid 47415139)
17. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11(4):203-17 (Pubitemid 26102522)
18. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7(8):583-91 (Pubitemid 44137488)
19. Large RG, Schug SA. Opioids for chronic pain of non-malignant origin-caring or crippling. Health Care Anal 1995;3(1):5-11
20. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104(3):570-87
21. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23(2):103-18 (Pubitemid 46145457)
22. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 2008;24(6):469-78
23. Koch T, Hollt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 2008;117(2):199-206
24. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007;91(2):199-211
25. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6(6):462-75 (Pubitemid 40780558)
26. Aasheim HC, Patzke S, Hjorthaug HS, Finne EF. Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis. Biochim Biophys Acta 2005;1723(1-3):1-7 (Pubitemid 40744666)
27. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3(7):475-86 (Pubitemid 34733429)
28. Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 2004;7(5):417-18 (Pubitemid 38544565)
29. Bruckner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 1997;275(5306):1640-3 (Pubitemid 27120539)
30. Himanen JP, Chumley MJ, Lackmann M, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 2004;7(5):501-9 (Pubitemid 38544589)
31. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10(3):165-80
32. Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007;19(5):534-42 (Pubitemid 350016850)
33. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-Daspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97(4):1108-16 (Pubitemid 37158698)
34. Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 2006;17(5):592-604 (Pubitemid 46389351)
35. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006;6(1):68-74 (Pubitemid 43103821)
36. Takasu MA, Dalva MB, Zigmond RE, Greenberg ME. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 2002;295(5554):491-5 (Pubitemid 34101638)
37. Battaglia AA, Sehayek K, Grist J, et al. EphB receptors and ephrin-B ligands regulate spinal sensory connectivity and modulate pain processing. Nat Neurosci 2003;6(4):339-40 (Pubitemid 36373976)
38. Slack S, Battaglia A, Cibert-Goton V, Gavazzi I. EphrinB2 induces tyrosine phosphorylation of NR2B via Srcfamily kinases during inflammatory hyperalgesia. Neuroscience 2008;156(1):175-83
39. Uchida H, Matsumoto M, Ueda H. Profiling of BoNT/C3-reversible gene expression induced by lysophosphatidic acid: ephrinB1 gene up-regulation underlying neuropathic hyperalgesia and allodynia. Neurochem Int 2009;54(3-4):215-21
40. Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006;109(1-2):57-77 (Pubitemid 41740815)
41. Ueda H. Peripheral mechanisms of neuropathic pain-involvement of lysophosphatidic acid receptor-mediated demyelination. Mol Pain 2008;4:11
42. Inoue M, Rashid MH, Fujita R, et al. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004;10(7):712-18 (Pubitemid 38937636)
43. Kobayashi H, Kitamura T, Sekiguchi M, et al. Involvement of EphB1 receptor/EphrinB2 ligand in neuropathic pain. Spine (Phila Pa 1976) 2007;32(15):1592-8 (Pubitemid 47051841)
44. Tan PH, Yang LC, Shih HC, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 2005;12(1):59-66
45. Hafner C, Becker B, Landthaler M, Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 2006;19(10):1369-77 (Pubitemid 44423085)
46. Vihanto MM, Plock J, Erni D, et al. Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J 2005;19(12):1689-91 (Pubitemid 41429531)
47. Cao JL, Ruan JP, Ling DY, et al. Activation of peripheral ephrinBs/EphBs signaling induces hyperalgesia through a MAPKs-mediated mechanism in mice. Pain 2008;139(3):617-31
48. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 2008;27(20):2934-40 (Pubitemid 351620455)
49. Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin Ther Targets 2009;13(9):1121-34
50. Sun R, Yan J, Willis WD. Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats. Neuroscience 2007;144(1):286-94 (Pubitemid 44839032)
51. Bogen O, Joseph EK, Chen X, Levine JD. GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican. Eur J Neurosci 2008;28(1):12-19
52. Stein AT, Ufret-Vincenty CA, Hua L, et al. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 2006;128(5):509-22 (Pubitemid 44664629)
53. Steinle JJ, Booz GW, Meininger CJ, et al. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem 2003;278(23):20681-6 (Pubitemid 36806369)
54. Steinle JJ, Meininger CJ, Chowdhury U, et al. Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell Signal 2003;15(11):1011-17 (Pubitemid 37130159)
55. Guan XH, Lu XF, Zhang HX, et al. Phosphatidylinositol 3-kinase mediates pain behaviors induced by activation of peripheral ephrinBs/EphBs signaling in mice. Pharmacol Biochem Behav 2010;95(3):315-24
56. Zhuang ZY, Xu H, Clapham DE, Ji RR. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004;24(38):8300-9 (Pubitemid 39280809)
57. Dong Y, Mao-Ying QL, Chen JW, et al. Involvement of EphB1 receptor/ephrinB1 ligand in bone cancer pain. Neurosci Lett 2011;496(3):163-7
58. Orikawa Y, Kato H, Seto K, et al. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 beta production in a cancer-induced pain model in mice. Mol Pain 2010;6:72
59. Liu S, Liu WT, Liu YP, et al. Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. Cancer Res 2011;71(13):4392-402
60. Liu WT, Li HC, Song XS, et al. EphB receptor signaling in mouse spinal cord contributes to physical dependence on morphine. FASEB J 2009;23(1):90-8